Shares of ProQR Therapeutics NV PRQR, +57.43% rocketed 66% to a near 3-year high in active morning trade Wednesday, to pace gainers on all the major exchanges, after the company said results from a phase 1/2 trial for the treatment of Leber’s congenital amaurosis, a cause for blindness in children, warranted the progression to a phase 2/3 trial. Volume topped 750,000 shares within the first five minutes after the open, compared with the full-day average of about 87,000 shares. The company said in the trial, QR-110 demonstrated “meaningful improvement” in vision, as early as two months after treatment and was stable by three months. The results met the company’s criteria to stop enrollment in the study and progress to a phase 2/3 trial. The stock was trading at the highest levels seen since November 2015. It has now run up more than 4-fold (up 308%) year to date, while the S&P 500 SPX, -0.42% has gained 8.1%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.